European Academy of Neurology (EAN) Congress 2024

Both galcanezumab and prednisone effectively relieve pain in people with medication overuse headache (MOH), with combination therapy using both medications yielding the greatest benefit, according to the results of a three-arm, head-to-head observational study. However, the use of prednisone is accompanied by an increased frequency of adverse events.

Argatroban appears to reduce neurological deficits in acute ischaemic stroke (AIS) patients with early neurological deterioration (END) who are undergoing thrombolytic therapy, without increasing the risk of symptomatic intracranial haemorrhage, according to the results of a meta-analysis.

Adding nipocalimab to standard-of-care (SoC) treatment significantly improves Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores in patients with generalized MG (gMG), according to the pivotal phase III Vivacity-MG3 study presented at EAN 2024.

The treatment effect of omaveloxolone in halting progression, based on change in mFARS score, is particularly pronounced in individuals with Friedreich's ataxia who had disease onset at ≤15 years of age, suggests a post hoc subgroup analysis of MOXIe Part 2 presented at EAN 2024.

A 10-week study presented at EAN 2024 has shown that a ketogenic or “keto” diet plus regular physical exercise may be beneficial for people with narcolepsy.